TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01325701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib is an inhibitor of BTK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib is an inhibitor of BTK
Study: NCT03405701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVM
Description: Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
Study: NCT02618707

Intervention type: OTHER
Intervention: Lactate
Description: Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
Study: NCT02582359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
Study: NCT03906786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
Study: NCT04604496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20MG
Description: PF-06882961 in 20 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20MG
Description: PF-06882961 in 20 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20MG
Description: PF-06882961 in 20 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20MG
Description: PF-06882961 in 20 mg oral tablet will be administered on Day 1
Study: NCT02691312

Intervention type: DEVICE
Intervention: Digital Retinography System
Description: The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
Study: NCT03165331

Intervention type: OTHER
Group type: OTHER
Intervention: Ung Face IT
Description: Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.

Intervention type: OTHER
Group type: OTHER
Intervention: Ung Face IT
Description: Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
Study: NCT02513693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard neuromuscular blockade
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
Study: NCT03701555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 150 mg
Description: PvP003 150 mg
Study: NCT00795600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir once daily plus insulin aspart at mealtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Insulin NPH once daily plus insulin aspart at mealtime
Study: NCT01286779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 326 (Recombinant factor IX)
Description: The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
Study: NCT00344682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: memantine 5mg - 20mg PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg - 20mg PO daily over 8 weeks
Study: NCT03320447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine 5% cream application
Description: The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
Study: NCT01952912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PkEP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OP
Study: NCT01197040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acid mycophenolic (Myfortic)
Description: patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
Study: NCT01925183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180mcg once weekly; subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180mcg once weekly; subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
Study: NCT02897544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Manualized Health Education Intervention
Study: NCT02167633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression surgery
Description: Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Radiotherapy
Description: Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
Study: NCT01381172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer System
Description: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention: Optimal medical therapy
Description: The control group receives optimal medical therapy only.
Study: NCT02620553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin
Description: There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
Study: NCT04499690

Intervention type: BEHAVIORAL
Intervention: Managing Cancer and Living Meaningfully
Description: A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
Study: NCT02491307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger.io Smartphone Application
Description: Daily use of the Ginger.io smartphone application
Study: NCT02440074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells
Description: Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
Study: NCT02350322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schoolmeal with fatty fish
Description: Schoolmeal with fatty fish three times a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schoolmeal without fish
Description: Schoolmeal with meat/cheese three times a week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Omega-3 capsules three times a week for 12 weeks
Study: NCT02620553

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral Placebo is given orally daily
Study: NCT04376541

Intervention type: DRUG
Intervention: Fentanyl
Description: amount of fentanyl used in both groups

Intervention type: DRUG
Intervention: Fentanyl
Description: amount of fentanyl used in both groups
Study: NCT04421144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthognathic surgery
Description: patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
Study: NCT00418392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple aspiration with minocycline pleurodesis
Description: Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: simple aspiration
Description: Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
Study: NCT02105506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil patch
Study: NCT02362880

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Florbetaben
Description: single dose of Florbetaben followed by PET scan

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Florbetaben
Description: single dose of Florbetaben followed by PET scan
Study: NCT01858662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases Resection ( multiple steep surgery possible)
Description: Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases Resection ( multiple steep surgery possible)
Description: Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracile
Description: 5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracile
Description: 5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin L
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin L
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
Study: NCT00592995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: 10 to 30 grams daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 to 30 grams daily
Study: NCT03175653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxycodone Pill A
Description: Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Pill B
Description: Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
Study: NCT01086657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Description: Inactive H5N1 Vaccine
Study: NCT03356912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone should be administred by oral route
Study: NCT02491320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-treatment acupuncture
Description: Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
Study: NCT01243333

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18]fluorodeoxyglucose
Description: Undergo PET scans with \[F-18\]fluorodeoxyglucose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18]fluorothymidine
Description: Undergo PET scans with fluorine \[F-18\]fluorothymidine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Water O-15
Description: Undergo PET scans with water O-15 tracers